STOCK TITAN

Invitation to Cosmo's 2020 results / 2021 outlook presentation conference call on 26 March 2021

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Cosmo Pharmaceuticals NV (SIX: COPN) will hold a telephone conference on March 26, 2021, at 2:00 PM CET to discuss its 2020 financial results and 2021 outlook. CEO Alessandro Della Chà and CFO Niall Donnelly will present during this session. Dial-in numbers are provided for participants from Switzerland, the UK, and the US. The presentation materials will be available on the company's website from 7:00 AM CET on the same day. Cosmo focuses on developing products for gastrointestinal disorders and has partnered with Medtronic for its AI device.

Positive
  • Partnership with Medtronic for distribution of GI Genius™, enhancing product visibility.
  • Focus on specialized gastrointestinal treatments, potentially increasing market share.
Negative
  • None.

DUBLIN, March 19, 2021 /PRNewswire/ -- Cosmo Pharmaceuticals NV (SIX: COPN) invites investors, financial analysts and business/lifescience journalists for a telephone conference on 26 March 2021 with CEO Alessandro Della Chà and CFO Niall Donnelly to discuss the 2020 results and 2021 outlook of the company.

Date:  Friday, 26 March 2021
Time: 02:00 pm CET

Dial-in numbers:
Switzerland / Europe: +41 (0) 58 310 50 00
United Kingdom: +44 (0) 207 107 06 13
United States: +1 (1) 631 570 56 13

The presentation and press release as well as the Annual Report 2020 will be available for download as of 07:00 am CET on 26 March 2021 on www.cosmopharma.com

About Cosmo Pharmaceuticals

Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has recently entered into a partnership with Medtronic for the global distribution of GI Genius its artificial intelligence device for use in coloscopies and GI procedures. Cosmo has licensed Aemcolo® to Red Hill Biopharma Ltd. for the US and has licensed Relafalk® to Dr. Falk Gmbh for the EU and other countries. For additional information on Cosmo and its products please visit the Company's website: www.cosmopharma.com

Calendar
2020 Full Year Results and 2021 Outlook - March 26, 2021
Annual General Meeting, Amsterdam - May 28, 2021

 

 

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/invitation-to-cosmos-2020-results--2021-outlook-presentation-conference-call-on-26-march-2021-301250513.html

SOURCE Cosmo Pharmaceuticals N.V.

FAQ

When is Cosmo Pharmaceuticals' conference call for 2020 results?

The conference call is scheduled for March 26, 2021, at 2:00 PM CET.

Who will present during Cosmo Pharmaceuticals' conference call?

CEO Alessandro Della Chà and CFO Niall Donnelly will present.

How can I access the presentation for Cosmo Pharmaceuticals' results?

The presentation will be available for download on their website from 7:00 AM CET on March 26, 2021.

What are the main focuses of Cosmo Pharmaceuticals?

Cosmo develops products for gastrointestinal disorders and endoscopy quality, including partnerships for AI devices.

COSMO PHARMA NV ORD

OTC:CMOPF

CMOPF Rankings

CMOPF Latest News

CMOPF Stock Data

1.12B
7.75M
47.29%
12.83%
Drug Manufacturers - General
Healthcare
Link
United States of America
Dublin